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Deregulation of inflammasome activation was recently identified to be involved in the pathogenesis 
of various inflammatory diseases. Although macrolide antibiotics display well described 
immunomodulatory properties, presumably involved in their clinical effects, their impact on 
inflammasome activation has not been investigated. We compared the influence of macrolides 
on cytokine induction in human monocytes. The role of intracellular azithromycin-accumulation 
was examined by interference with Ca++-dependent uptake. We have also analysed the signalling 
cascades involved in inflammasome activation, and substantiated the findings in a murine sepsis 
model. Azithromycin, but not clarithromycin or roxithromycin, specifically inhibited IL-1α and 
IL-1β secretion upon LPS stimulation. Interference with Ca++-dependent uptake abolished the 
cytokine-modulatory effect, suggesting a role of intracellular azithromycin accumulation in the 
modulatory role of this macrolide. Azithromycin’s inhibiting effects were observed upon LPS, but 
not upon flagellin, stimulation. Consistent with this observation, we found impaired induction of 
the LPS-sensing caspase-4 whereas NF-κB signalling was unaffected. Furthermore, azithromycin 
specifically affected IL-1β levels in a murine endotoxin sepsis model. We provide the first evidence 
of a differential impact of macrolides on the inflammasome/IL-1β axis, which may be of relevance in 
inflammasome-driven diseases such as chronic obstructive pulmonary disease or asthma.
Macrolides are a group of antibiotics known to have a broad range of immune-modulating properties 
apart from their antimicrobial effects1,2. Different macrolides have proven effective in preventing exac-
erbations of chronic obstructive pulmonary disease (COPD)3–6 and non-cystic fibrosis bronchiectasis7, 
improving lung function in cystic fibrosis patients8 and in ameliorating the disease course in subgroups 
of asthma patients9. Intriguingly, these effects were reached in dose regimens considerably lower than 
used in antimicrobial chemotherapy. Therefore, immune-modulating properties are considered respon-
sible for at least parts of their clinical effects.
Inflammasomes are large cytosolic multiprotein complexes mediating innate immune activation 
through the control of caspase activity in response to various stimuli10. This activation results in a variety 
of cellular adaptations including the induction of a programmed cell death termed “pyroptosis” which 
enhances microbial killing11, and most importantly, the maturation and cleavage of the pro-inflammatory 
cytokines IL-1α , IL-1β and IL-18. The first step in the production of these cytokines is induced by NF-κ B 
activation which leads to the transcription of premature forms of the cytokines12. Next, inflammatory 
caspases are activated by specific stimuli and cleave the cytokines to generate their active forms. Recent 
findings have established a dual role of LPS in the induction of both steps of IL-1β maturation13. The 
human homologue of the murine caspase-11, the inflammatory caspase-4, was shown to be an intracel-
lular sensor of LPS and is, therefore, regarded responsible for this second functionality of LPS14.
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The activation of inflammasome signalling by pathogens is an innate defence mechanism leading to 
microbial clearance15; however, excessive inflammasome activation is equally detrimental for the host16. 
Deregulation of inflammasome signalling was shown to be involved in a variety of human conditions 
as autoimmune diseases17, graft-versus-host disease18, as well as type 2 diabetes19. Recently, this dereg-
ulation was identified to be involved in the pathogenesis of respiratory diseases as well20. Downstream 
molecules of the inflammasome-cascade such as IL-1α , IL-1β and IL-18 were found to be increased in 
patients with COPD21–23 and several experimental studies have substantiated the causative role of this 
pathway in cigarette-smoke induced inflammation21,22,24. Furthermore, compelling evidence exists for the 
involvement of the inflammasome in asthma pathogenesis25.
Respiratory illnesses constitute a major clinical application of macrolide antibiotics. However, 
although immune-modulating properties of macrolide antibiotics are well investigated, studies on the 
impact on inflammasome signalling are lacking. Furthermore, comparative studies on the effects of dif-
ferent macrolides on human immune cell function are rare, and in studies searching for favourable 
immune-modulating properties, the choice of which macrolide to use is based only on pharmacoki-
netic considerations. Therefore, we set out to analyse the effect of macrolides on inflammatory caspase 
activation and IL-1 secretion in human immune cells and compared the effects of the most prominent 
macrolide compounds on this pathway.
Results
Azithromycin specifically inhibits IL-1β secretion of human monocytes. Since clinical evidence 
suggests beneficial effects of azithromycin on inflammasome-driven diseases4,9, we initially focused on 
this compound when analysing the impact of macrolides on pro-inflammatory cytokine release. In line 
with previous reports26,27, LPS stimulation alone was sufficient to induce a potent IL-1β release from 
human monocytes (Suppl. Table S1). Intriguingly, when stimulating human monocytes with LPS, azith-
romycin treatment significantly inhibited IL-1β secretion in a dose-dependent manner (Fig.  1a, Suppl. 
Table S1), whereas the induction of other monocyte-derived pro-inflammatory cytokines such as tumor 
necrosis factor (TNF)-α , IL-6, and IL-8 was unaffected (Fig. 1b–d, Suppl. Table S1). In contrast, when 



































































Figure 1. Azithromycin specifically inhibits IL-1β secretion upon LPS stimulation in human monocytes. 
Panel a)-d) show the impact of azithromycin on cytokine release of LPS or flagellin stimulated human 
monocytes. Cells were treated with the indicated concentrations of azithromycin and stimulated with either 
100 ng/ml LPS or 100 ng/ml Flagellin for 20 h. After co-incubation, cell culture supernatants were analysed 
for the presence of the indicated cytokines by Luminex®. Values are expressed as mean ± SEM from 6 
independent experiments. *Significant compared to LPS/flagellin alone, p < 0.05 calculated by paired t-test.
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treatment had no substantial effect on IL-1β secretion (Fig. 1a, Suppl. Table S1), and similar to LPS stim-
ulation, the release of the other cytokines (TNF-α , IL-6, and IL-8) was not affected (Fig.  1b–d, Suppl. 
Table S1). Azithromycin in the doses used in these experiments did not exhibit significant effects on cell 
viability (Suppl. Fig. S1). These findings outline a specific and dose-dependent impact of azithromycin 
on the inflammatory caspase axis, leading to the inhibition of IL-1β maturation in human monocytes.
Neither clarithromycin nor roxithromycin modulate cytokine production in human mono-
cytes. Next, we wanted to find out whether other macrolides have an effect on IL-1β secretion in 
monocytes as well. For this purpose, we analysed the impact of clarithromycin and roxithromycin on 
monocytes stimulated with LPS or flagellin. In contrast to azithromycin, neither clarithromycin nor rox-
ithromycin affected IL-1β secretion (Fig. 2a,b, Suppl. Table S1). Induction of the other pro-inflammatory 
cytokines was also not altered by treatment with these compounds (Suppl. Fig. S2, Suppl. Table S1). These 
experiments established a unique IL-1β modulating effect of azithromycin among the macrolides studied.
Interference with azithromycin uptake abrogates its cytokine-modulating effect. Azithromycin 
is known to accumulate in leucocytes to a considerably higher degree than any other macrolide anti-
biotic28,29. Drug transport through the plasma membrane (and thus intracellular accumulation) is 
Ca++-dependent and is assumedly operated via Ca++-channels30,31. We hypothesized that differences 
in intracellular accumulation were responsible for the diverging results observed in our study. To test 
this hypothesis, we disrupted the transmembrane transport of azithromycin by depleting extracellular 
calcium as well as utilising the L-type Ca++-channel blocker verapamil, two approaches shown to inhibit 
macrolide uptake in leucocytes30,31. As expected, both strategies interfering with azithromycin uptake 
resulted in the abrogation of its IL-1β modulating effect (Fig. 3a,b, Suppl. Table S1). These findings sug-
gest a role of intracellular azithromycin accumulation in the modulatory effects of this macrolide which 
might be of relevance for the differential effects among macrolides.
Figure 2. Clarithromycin and roxithromycin have no substantial impact on IL-1β secretion. Panel a) 
and b) show the impact of clarithromycin and roxithromycin, respectively, on LPS or flagellin stimulated 
IL-1β release by human monocytes. Cells were treated with the indicated concentrations of the drugs 
and stimulated with either 100 ng/ml LPS or 100 ng/ml flagellin for 20 h. After co-incubation, cell culture 
supernatants were analysed for the presence of the indicated cytokines by Luminex®. Values are expressed as 
mean ± SEM from 4 independent experiments.
www.nature.com/scientificreports/
4Scientific RepoRts | 5:12016 | DOi: 10.1038/srep12016
Azithromycin impairs intracellular LPS-sensing. The finding that azithromycin inhibits IL-1β 
secretion upon LPS stimulation without affecting the production of other pro-inflammatory cytokines, 
suggested an inhibitory effect of the drug on IL-1β maturation, since the first step of cytokine induction 
(NF-κ B activation) would also affect the production of other cytokines. Furthermore, the restriction of 
the effect to LPS stimulation suggested that the mechanism either included the NLRP3 inflammasome 
or directly involved LPS recognition. In order to assess whether a disturbance of intracellular LPS sens-
ing might be responsible for azithromycin’s effects, we measured whether there is an uptake of LPS into 
intracellular compartments of human monocytes in the doses utilised in our cytokine assays. To this 
end, we made use of FITC-labelled LPS to detect internalisation of this compound after quenching of 
extracellular fluorescence. Here, we were able to detect a significant increase in fluorescence in FITC-LPS 
treated cells, when compared to both LPS-stimulated (37 °C) and/or FITC-LPS treated (4 °C) cultures, 
thus indicating internalisation of the compound (Fig.  4a). Since we had detected intracellular LPS, a 
disturbance of LPS sensing by azithromycin was a feasible option. Inflammatory caspase-4, a human 
homologue of murine caspase-11, has recently been identified to function as an intracellular LPS 
receptor14. When analysing the impact of azithromycin on the induction of this caspase, we found a sig-






Azithromycin (µg/ml) - 1 2 4 8 16
LPS (100 ng/ml) + + + + + +













Azithromycin (µg/ml) - 1 2 4 8 16
LPS (100 ng/ml) + + + + + +










Figure 3. Interference with Ca++-dependent intracellular azithromycin accumulation abrogates 
the cytokine-modulating effect. Panel a) shows the impact of azithromycin on LPS stimulated human 
monocytes in the presence of 10 mM EGTA. Panel b) shows the impact of azithromycin IL-1β production of 
verapamil pretreated (30 min) and LPS stimulated monocytes in the presence verapamil. Cells were treated 
with the indicated concentrations of azithromycin and stimulated with 100 ng/ml LPS for 20 h. After co-
incubation, cell culture supernatants were analysed for the presence of the indicated cytokines by Luminex®. 
Values are expressed as mean ± SEM from 3 independent experiments.
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was not affected by azithromycin treatment (Fig. 4c). Once we identified that azithromycin’s effects were 
mediated by interference with inflammatory caspase signalling, we wondered whether other cytokines 
regulated by this axis were also affected by azithromycin treatment. Therefore, we analysed the induction 
Figure 4. Azithromycin inhibits the induction of caspase-4 without affecting NF-κB transcription. 
Panel a) depicts the intracellular accumulation of FITC-labelled LPS at 37 °C into monocytes after 4 h 
incubation. Cells incubated at 4 °C were included as controls. Quenching with trypan blue was performed 
to exclude extracellular fluorescence. A representative of 2 independent experiments performed in triplicates 
is shown. Panel b) depicts a representative immunoblot result and the summary of the densitometric 
analysis of 3 independent experiments of caspase-4 induction in azithromycin treated and LPS stimulated 
human monocytes. Panel c) shows the impact of azithromycin and the NF-κ B inhibitory protein SN50 
(positive control) on LPS induced NF-κ B transcription in an eGFP-NF-κ B THP-1 monocyte reporter cell 
line. Panel d) shows the impact of azithromycin on IL-1α release of LPS stimulated human monocytes. 
Cells were treated with the indicated concentrations of azithromycin and stimulated with 100 ng/ml LPS for 
20 h. Supernatants were analysed for the presence of IL-1α by Luminex®. Values in Panel a) are expressed 
as Mean ± SEM of triplicate values of a representative experiment.*Significant compared to the indicated 
samples, *p < 0.05, **p < 0.01 calculated by unpaired t-test. b)+ c)+ d) are expressed as mean ± SEM of 3 
independent experiments. *Significant compared to LPS alone, p < 0.05 calculated by paired t-test.
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of IL-1α and IL-18, and found an intense and dose-dependent down-modulation of IL-1α production 
upon LPS stimulation (Fig.  4d, Suppl. Table S1). In contrast, we were not able to detect IL-18 in cell 
culture supernatants (data not shown). With these experiments, we were able to identify an impact of 
azithromycin on inflammasome formation, which involves the inhibition of intracellular LPS sensing 
mediated by caspase-4.
Azithromycin affects IL-1β secretion in vivo. In order to further substantiate our findings, we 
assessed the impact of azithromycin on cytokine induction in a murine model of LPS sepsis. In line with 
our in vitro observations, we found a selective down-modulation of IL-1β levels in the course of endo-
toxin sepsis whereas other pro-inflammatory cytokines remained unaffected by the treatment (Fig. 5a–c). 
Although the results did not reach statistical significance, probably due to the high variability in this 
model, the specificity of azithromycin’s effects on cytokine production is remarkable. These findings 
substantiate the potential impact of our findings for an in vivo situation which might be of relevance in 
clinical conditions as well.
Discussion
Several clinical studies addressing the impact of macrolides on inflammation-driven diseases found a 
therapeutic benefit of macrolides which was not exclusively attributable to their antimicrobial proper-
ties3,6,9. These findings have stimulated a debate about whether a long-term macrolide regimen should 
become part of treatment guidelines in patients with chronic respiratory diseases such as COPD and 
cystic fibrosis32,33.
The aim of this study was to analyse and compare the impact of macrolides on the inflammasome 
axis, which was recently identified as a central regulator of respiratory diseases, a major field of clinical 
macrolide application. We have shown that azithromycin selectively inhibits IL-1 production in vitro 
and in vivo. Azithromycin did not affect NF-κ B signalling in monocytes, but impaired the induction of 
the inflammatory caspase-4, which is an early regulator of the inflammasome pathway and an intracel-























































Figure 5. Azithromycin affects IL-1β secretion in vivo. Panel a)-c) show the impact of azithromycin 
treatment on cytokine levels in a murine LPS-sepsis model. Female C57BL/6 (n = 10 mice per group) were 
injected with 50 mg/kg BW azithromycin or placebo and subsequently were injected with 2.5 mg/kg BW LPS. 
Serum samples were obtained 6 h after injection and cytokines were measured by Luminex®. Results are 
depicted as mean ± SEM.
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effects in human monocytes. Experiments interfering with Ca++-dependent uptake indicated a role of 
intracellular accumulation of azithromycin in its cytokine-modulatory effects.
Although a plethora of work analysing the immune-modulating properties of macrolides has been 
performed1, studies on the cytokine-modulating properties of these drugs on primary human innate 
immune cells are limited. Similar to our results, Vrančić et al. found no alterations of TNF-α and IL-6 
production of IFN-γ /LPS stimulated human monocytes when co-treated with azithromycin34. Kikuchi 
et al. studied the impact of clarithromycin on IL-8 secretion of adherence-purified monocytes and the 
THP-1 monocytic cell line. In contrast to our findings, these authors were able to detect inhibition of 
IL-8 secretion. Since we utilized highly purified CD14+ cells, the inconsistency might be explained by the 
different cell isolation procedures and cell treatment. Furthermore, Kikuchi et al. used higher amounts 
of LPS (1 μ g/ml vs 100 ng/ml in our study) for stimulation, which might influence the outcome as well35. 
The only other study assessing potential differences in the cytokine-modulating effects of azithromycin 
and clarithromycin in primary human monocytes was performed by Khan et al.36. Similar to our findings, 
differing modulating properties of the drugs were observed. However, in this study, slight reductions also 
in IL-6 and TNF-α levels were observed when the cells were treated with clarithromycin. Intriguingly, 
similar to our results, azithromycin potently inhibited IL-1α secretion in this study. Nevertheless, since 
the regulation of IL-1 secretion by the inflammasome axis was then unknown, the inflammasome could 
not be deduced to be the molecular target of azithromycin.
Macrolides are known to accumulate in leucocytes, and their intracellular concentrations are about 
100-fold higher than that in plasma37. The doses utilized in this study mirror tissue concentrations deter-
mined by pharmacokinetic studies which range from 5 to 10 μ g/ml38. Azithromycin is known to accu-
mulate intracellularly to a much higher extent than clarithromycin or roxithromycin28,29. The dibasic 
structure of azithromycin, which is unique among macrolides, causes enrichment in acidic phagoso-
mal compartments due to ion-trapping and a rather slow release from intracellular compartments39. 
Transport through the plasma membrane is known to be mediated by a Ca++-dependent mechanism31. 
In this study, we have utilised two strategies known to inhibit macrolide accumulation in leucocytes30,31. 
The observation that interruption of azithromycin’s transmembrane transport can abolish its IL-1β mod-
ulating effects suggests a role of azithromycin’s intracellular accumulation in the mediation of its effects. 
Taking into account the established differences in intracellular accumulation among macrolides, the 
varying ability of macrolides to inhibit the inflammasome axis due to differential intracellular presence 
is conceivable. Nevertheless, additional experiments are needed to further elucidate the mechanisms 
underlying the diverging immune-modulatory properties of macrolides.
Several molecular targets have been implicated in azithromycin’s immune-modulating effects1. 
However, our observations in human monocytes narrowed down the spectrum of potential targets to 
the pathways involved in IL-1β secretion, NF-κ B- and inflammasome signalling.
In contrast to previous reports on azithromycin’s impact on the NF-κ B pathway in monocytes34,40, 
we were not able to detect an inhibition of NF-κ B signalling in our model. Since previous reports uti-
lised dual stimulation models in their assays (Vrančić et al. utilised an IFN-γ /LPS-stimulation model34, 
Kobayashi et al. PMA priming prior to LPS stimulation40), varying effects might be due to differences in 
signalling cascades induced in the respective models.
Recent advances have identified the inflammatory caspase-4 and the murine homologue caspase-11 as 
central upstream regulators of the “noncanonical inflammasome” cascade41. These caspases were found to 
be crucial regulators of endotoxin-induced immune responses. In particular, they mediate LPS-induced 
lethality in endotoxin sepsis13,42. Sollberger et al. elegantly showed that caspase-4 is an upstream regulator 
of caspase-1 activity, and, additionally, has intrinsic IL-1β processing abilities43. The findings by Shi 
et al., who identified caspase-4 as a direct receptor for LPS, shed further light on the role of this enzyme 
in the mediation of endotoxin-induced immune responses14. Since azithromycin’s effects were observed 
after endotoxin, but not flagellin stimulation, we focused on this inflammatory caspase in the search for 
azithromycin’s target in inflammasome activation. We were able to show an impairment of caspase-4 
induction after azithromycin treatment, which provides a coherent explanation for the specificity of 
its effects. Additionally, we found a dose-dependent down-modulation of another caspase-processed 
cytokine, IL-1α , which provides further evidence for azithromycin’s impact on this pathway. Although 
the induction of IL-1β maturation by caspase-4 is consistent in literature, the involvement of downstream 
mediators of this effect, particularly caspase-1, is controversial42,43. Future studies might clarify this issue 
and help to further elucidate the detailed mechanism of azithromycin’s action.
The specific inhibition of IL-β production by azithromycin in a murine endotoxin sepsis model, 
points towards a similar effect on caspase-11, the murine homologue of human caspase-4. In the setting 
of endotoxin sepsis, these inflammatory caspases are not only known to mediate IL-1β secretion, but 
also, and more importantly, are crucial regulators of lethality in endotoxemia13,42. The accordance of our 
in vitro data with the findings in this in vivo model expands our observations to pathologically relevant 
situations and might encourage research on the impact of azithromycin on this axis in similar conditions 
in humans. Furthermore, clinical research needs to assess whether our observations gained in a short 
term stimulation model are reproducible in long-term treatment regimens with different macrolides in 
the therapy of clinical conditions.
We herewith provide the first evidence of azithromycin’s specific inhibition of the pro-inflammatory 
cytokines IL-1α and IL-1β in human innate immune cells by impairing intracellular LPS sensing of the 
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inflammatory caspase-4. Furthermore, we have shown that there are fundamental differences between 
macrolides in targeting the inflammasome axis. Therefore, our findings suggest that azithromycin might 
be the macrolide of choice in the treatment of diseases involving deregulated inflammasome activation. 
However, since this pathway plays an important role in microbial clearance as well, additional studies 
are required in order to assess whether the immune-modulating properties reported in this study result 
in a favourable disease outcome.
Materials and Methods
Ethical considerations, cell isolation and culture. This study was approved by the local ethics 
committee of the Medical University of Vienna (EC number 1381/2014) and conducted according to the 
Declaration of Helsinki and Good Scientific Practice guidelines. Buffy-coats from healthy donors were 
obtained from the Red Cross Austria. Informed consent was obtained from all volunteers prior to dona-
tion. Monocyte isolation was performed as previously described44. In brief, peripheral blood mononu-
clear cells (PBMCs) were obtained by density-gradient separation, utilizing endotoxin-free Lymphoprep 
(Nycomed Pharma AS, Oslo, Norway). Subsequently, the CD14+ monocyte fraction was isolated by 
MACS® separation according to the manufacturer’s protocol (Miltenyi Biotec, Bergisch Gladbach, 
Germany). After magnetic cell sorting, the purity of the cells was assessed by flow cytometry (commonly 
>99%). Monocytes were then washed once in phosphate-buffered saline (PBS; PAA, Pasching, Austria) 
and resuspended in RPMI 1640 (PAA) containing 10% fetal calf serum (PAA) and antibiotics (100 IU/
ml penicillin and 100 μ g/ml streptomycin; Sigma-Aldrich, St. Louis, MO).
Cytokine release assay. Monocytes were resuspended at a density of 1 × 106/ml in medium as 
described above. The cell suspension was seeded on 96-well plates, and azithromycin, clarithromycin, or 
roxithromycin (all obtained from Sigma) were added in the indicated concentrations just before stimu-
lation with either 100 ng/ml LPS 0111:B4 (L-4391, Sigma) or 100 ng/ml flagellin (Invivogen, San Diego, 
CA). After 18–20 h incubation, the supernatants were collected, centrifuged for 5 min at 400 × g and used 
for further analysis. In the Ca++-depleting experiments, cells were treated as described above but were 
stimulated in medium containing 10 mM EGTA (Sigma). In the Ca++-channel blocking experiments, 
cells were incubated with 125 μ M verapamil (Sigma) for 30 min before treatment with azithromycin and 
LPS stimulation (verapamil was not removed during stimulation). Cytokine measurements of TNF-α , 
IL-1β , IL-1α , IL-6, and IL-8, were performed by Luminex® testing using specific matched-pair antibodies 
and recombinant cytokines as standards (Merck Millipore, Billerica, MA). IL-18 was measured with a 
human IL-18 Instant ELISA (eBioscience, Vienna, Austria; detection limit: 9.2 pg/ml).
Cell viability assay. Monocytes were treated as described for the cytokine release assay. After 20 h 
co-incubation with LPS and azithromycin, cells were detached by washing with PBS/4 mM EDTA, 
washed once in PBS and resuspended in 25 μ l PBS/EDTA. Shortly before performing flow cytometric 
analysis, propidium iodide was added to a final concentration of 50 ng/ml.
Intracellular LPS measurement. Monocytes (1 × 106/ml) were incubated with either unlabelled LPS 
0111:B4 (Sigma) or FITC-labelled LPS 0111:B4 (Sigma) at 37 °C for 4 h, baseline controls incubated at 
4 °C were included in the analysis. After the incubation period, cells were detached with Accutase (PAA), 
washed with PBS and quenching was performed with trypan blue (Glycotope Biotechnology GmbH, 
Heidelberg, Germany) before flow cytometric analysis on a BD LSRFortessa™ (Becton Dickinson, 
Franklin Lakes, NJ).
Western blot analysis. Monocytes (1 × 106/ml) were incubated with azithromycin in the indicated 
concentrations before adding 1 μ g/ml LPS 0111:B4. After 18 h of incubation, the cells were detached by 
scraping, washed in ice-cold PBS, and lysed in 0.5% Triton-X buffer for 5 min on ice. After lysis, the 
suspension was centrifuged for 5 min at 13000 × g, and the supernatant was utilized for further analysis. 
Western blotting was performed as described previously44. Anti-caspase-4 antibody (MBL International, 
Woburn, MA; clone 4B9) and anti-GAPDH (Cell Signaling Technology, Danvers, MA) were used in 
a dilution of 1:1000. Detection was performed with Pierce® ECL Western blotting substrate (Thermo 
Fisher Scientific, Waltham, MA) on a LAS-4000 (Fujifilm, Tokyo, Japan). Data analysis, quantification, 
and processing were performed with Fiji (ImageJ) image processing software.
NF-κB-GFP reporter cell assay. For the generation of THP-1-NF-kB-GFP reporter cells, a slightly 
modified form of a previously described GFP-NF-kB reporter construct45 was retrovirally transduced in 
THP-1 cells (ATCC #TIB-202). Single cell clones were established by limiting dilution culturing. A cell 
clone that was GFP-negative in an unstimulated state and strongly upregulated GFP expression upon LPS 
or PMA/ionomycin treatment was selected for further use.
The reporter cells were incubated with the indicated amounts of azithromycin, LPS and SN50 (Enzo 
Life Sciences, Inc.; Farmingdale, NY) for 20 h before flow cytometric analysis of eGFP fluorescence on 
a BD LSRFortessa™ .
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Murine LPS-sepsis. All animal experiments were reviewed by the Animal Ethics Board of the Medical 
University of Vienna and approved by the Austrian Ministry of Economy and Science (BMWF-66.009-
0027-II/3b/2014). All animal husbandry and experimentation was performed in accordance with the 
Federation of Laboratory Animal Science Associations (FELASA) guidelines and national law.
Eight-week-old female C57BL/6 mice (10 mice per group) from in-house breeding (originally 
obtained from Jackson Laboratories, Bar Harbor, ME) were used for the experiment. Mice were injected 
intraperitoneally with 50 mg/kg body weight (BW) azithromycin (Sigma) or placebo (DMSO as solvent 
control) before receiving an injection of 2.5 mg/kg BW LPS 0111:B4 (L-2630, Sigma). After 6 h, blood 
samples were obtained from tail vein puncture, and the serum was centrifuged and subjected to cytokine 
analysis by Luminex® (as above).
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